In vitro activity of AT-4140 against clinical bacterial isolates.
AUTOR(ES)
Kojima, T
RESUMO
The activity of AT-4140, a new fluoroquinolone, was evaluated against a wide range of clinical bacterial isolates and compared with those of existing analogs. AT-4140 had a broad spectrum and a potent activity against gram-positive and -negative bacteria, including Legionella spp. and Bacteroides fragilis. The activity of AT-4140 against gram-positive and -negative cocci, including Acinetobacter calcoaceticus, was higher than those of ciprofloxacin, ofloxacin, and norfloxacin. Its activity against gram-negative rods was generally comparable to that of ciprofloxacin. Some isolates of methicillin-resistant Staphylococcus aureus (MIC of methicillin, greater than or equal to 12.5 micrograms/ml) were resistant to existing quinolones, but many of them were still susceptible to AT-4140 at concentrations below 0.39 micrograms/ml. The MICs of AT-4140, ciprofloxacin, ofloxacin, and norfloxacin for 90% of clinical isolates of methicillin-resistant S. aureus were 0.2, 12.5, 6.25, and 100 micrograms/ml, respectively. AT-4140 was bactericidal for each of 20 clinical isolates of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa at concentrations near the MICs. AT-4140 inhibited the supercoiling activity of DNA gyrase from E. coli.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=172799Documentos Relacionados
- In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
- In vitro activity of sparfloxacin (CI-978; AT-4140) against clinical isolates from cancer patients.
- In vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates.
- In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates.
- In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.